shutterstock_2139553995_t_schneider

T. Schneider / Shutterstock.com

7 June 2022Big PharmaSarah Speight

Arbutus, Genevant reject Moderna’s vaccine patent defence

Moderna’s bid to avoid a COVID-19 patent claim has been rejected by two pharma companies that are suing the vaccine manufacturer for infringing its drug delivery technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Moderna aims to offset COVID vaccine lawsuit to US govt

10 May 2022 Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.

More on this story

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Moderna aims to offset COVID vaccine lawsuit to US govt

10 May 2022 Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.

More on this story

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Moderna aims to offset COVID vaccine lawsuit to US govt

10 May 2022 Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility